PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11696371-1 2001 Lovastatin treatment caused down-regulation of the insulin-responsive glucose transporter 4 (Glut4) and up-regulation of Glut1 in 3T3-L1 adipocytes. Lovastatin 0-10 insulin Homo sapiens 51-58 11716532-8 2001 Wortmannin and LY294002, PI3-kinase inhibitors, as well as lovastatin and PD152440, Ras farnesylation inhibitors, and MEK inhibitor PD98059 abolished the insulin repression of ALAS transcription. Lovastatin 59-69 insulin Homo sapiens 154-161 11696371-3 2001 Lovastatin had no effect on cell cholesterol levels, but its effects were reversed by mevalonate, demonstrating that inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. Lovastatin 0-10 insulin Homo sapiens 162-169 9430371-6 1997 Lovastatin efficiently inhibited [3H]thymidine uptake promoted by all mitogens tested (76-87%); however, it significantly inhibited upregulation of c-fos mRNA levels induced only by insulin (33-67%, P < 0.05) and IGF-I (31 57%, P < 0.05). Lovastatin 0-10 insulin Homo sapiens 182-189 11387965-0 1999 [Effects of lovastatin on plasma lipid, plasma glucose and insulin metabolism of patients with type II B hyperlipemia]. Lovastatin 12-22 insulin Homo sapiens 59-66 11387965-1 1999 This study was directed at the effects of lovastatin on plasma glucose and insulin metabolism of patients with Type II B hyperlipemia. Lovastatin 42-52 insulin Homo sapiens 75-82 9459136-19 1997 Also, plasma acetylhydrolase activity significantly correlated with fasting plasma insulin levels before lovastatin therapy but not after. Lovastatin 105-115 insulin Homo sapiens 83-90 8935222-0 1996 Lovastatin lowers serum cholesterol levels in non-insulin-dependent diabetes mellitus patients without altering their insulin sensitivity. Lovastatin 0-10 insulin Homo sapiens 50-57 9381994-0 1997 Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients. Lovastatin 33-43 insulin Homo sapiens 64-71 8935222-3 1996 The influence of lovastatin on insulin sensitivity was evaluated in twelve Chinese non-insulin-dependent diabetes mellitus (NIDDM) patients with hypercholesterolemia. Lovastatin 17-27 insulin Homo sapiens 31-38 29471671-11 2018 Lovastatin administration to rats decreased hepatic cholesterol content, disrupted lipid rafts and decreased insulin-induced Ca2+ signaling in hepatocytes, and delayed liver regeneration after PH. Lovastatin 0-10 insulin Homo sapiens 109-116 7836430-2 1995 Lovastatin blocked an ability of insulin to activate p21ras and mitogen-activated protein kinase. Lovastatin 0-10 insulin Homo sapiens 33-40 7836430-3 1995 Lovastatin also significantly (p < 0.01) reduced insulin effects on thymidine incorporation and glucose incorporation into glycogen. Lovastatin 0-10 insulin Homo sapiens 52-59 1953779-1 1991 Human fibroblasts treated with the antihypercholesterolaemic drug, lovastatin, displayed a diminished signaling response to epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Lovastatin 67-77 insulin Homo sapiens 155-162 15584598-7 2004 Body weight loss and diminished insulin resistance in patients with AH concurrent MS require long use of lovastatin along with low-calorie diet and exercises. Lovastatin 105-115 insulin Homo sapiens 32-39 26491824-10 2015 Of these, we found to be interesting the association with monacolin K, a natural statin that reduces cholesterol levels starting point of the synthesis of steroids, including androgens, and lipoic acid, known for its anti-inflammatory, antioxidant and insulin-sensitizing activity. Lovastatin 58-69 insulin Homo sapiens 252-259 18078859-4 2008 Our data show that treatment with lovastatin results in a marked improvement in insulin sensitivity characterized by an increase in glucose disappearance rate during the insulin tolerance test. Lovastatin 34-44 insulin Homo sapiens 80-87 18078859-4 2008 Our data show that treatment with lovastatin results in a marked improvement in insulin sensitivity characterized by an increase in glucose disappearance rate during the insulin tolerance test. Lovastatin 34-44 insulin Homo sapiens 170-177 18078859-6 2008 Our data also show that lovastatin treatment was associated with an increase in insulin-stimulated insulin receptor substrate (IRS) 1/phosphatidylinositol 3-kinase/Akt pathway in the liver and muscle of HFD-fed rats in parallel with a decrease in the inflammatory pathway (c-jun N-terminal kinase and I kappa beta kinase (IKKbeta)/inhibitor of kappaB/nuclear factor kappaB) related to insulin resistance. Lovastatin 24-34 insulin Homo sapiens 80-87 18078859-6 2008 Our data also show that lovastatin treatment was associated with an increase in insulin-stimulated insulin receptor substrate (IRS) 1/phosphatidylinositol 3-kinase/Akt pathway in the liver and muscle of HFD-fed rats in parallel with a decrease in the inflammatory pathway (c-jun N-terminal kinase and I kappa beta kinase (IKKbeta)/inhibitor of kappaB/nuclear factor kappaB) related to insulin resistance. Lovastatin 24-34 insulin Homo sapiens 99-106 18078859-6 2008 Our data also show that lovastatin treatment was associated with an increase in insulin-stimulated insulin receptor substrate (IRS) 1/phosphatidylinositol 3-kinase/Akt pathway in the liver and muscle of HFD-fed rats in parallel with a decrease in the inflammatory pathway (c-jun N-terminal kinase and I kappa beta kinase (IKKbeta)/inhibitor of kappaB/nuclear factor kappaB) related to insulin resistance. Lovastatin 24-34 insulin Homo sapiens 99-106 14517078-5 2003 Using a fungal metabolite, lovastatin, to block the p21Ras signaling pathway of insulin, we found that lovastatin inhibited the secretion of HBsAg into culture medium in Hep3B cells; however, the involvement of p21Ras-MAPKs was excluded in this effect. Lovastatin 27-37 insulin Homo sapiens 80-87 14517078-5 2003 Using a fungal metabolite, lovastatin, to block the p21Ras signaling pathway of insulin, we found that lovastatin inhibited the secretion of HBsAg into culture medium in Hep3B cells; however, the involvement of p21Ras-MAPKs was excluded in this effect. Lovastatin 103-113 insulin Homo sapiens 80-87